These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 25445374)

  • 1. Chronic levodopa treatment alters expression and function of dopamine D3 receptor in the MPTP/p mouse model of Parkinson's disease.
    Cote SR; Kuzhikandathil EV
    Neurosci Lett; 2015 Jan; 585():33-7. PubMed ID: 25445374
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overexpression of the dopamine D3 receptor in the rat dorsal striatum induces dyskinetic behaviors.
    Cote SR; Chitravanshi VC; Bleickardt C; Sapru HN; Kuzhikandathil EV
    Behav Brain Res; 2014 Apr; 263():46-50. PubMed ID: 24462727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term treatment with l-DOPA and an mGlu5 receptor antagonist prevents changes in brain basal ganglia dopamine receptors, their associated signaling proteins and neuropeptides in parkinsonian monkeys.
    Morin N; Jourdain VA; Morissette M; Grégoire L; Di Paolo T
    Neuropharmacology; 2014 Apr; 79():688-706. PubMed ID: 24456747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dopamine D3 receptor stimulation underlies the development of L-DOPA-induced dyskinesia in animal models of Parkinson's disease.
    Visanji NP; Fox SH; Johnston T; Reyes G; Millan MJ; Brotchie JM
    Neurobiol Dis; 2009 Aug; 35(2):184-92. PubMed ID: 19118628
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro and in vivo characterization of the agonist-dependent D3 dopamine receptor tolerance property.
    Cote SR; Kuzhikandathil EV
    Neuropharmacology; 2014 Apr; 79():359-67. PubMed ID: 24316466
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Behavioral and cellular dopamine D
    Lanza K; Meadows SM; Chambers NE; Nuss E; Deak MM; Ferré S; Bishop C
    Neuropharmacology; 2018 Aug; 138():304-314. PubMed ID: 29936243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Buspirone anti-dyskinetic effect is correlated with temporal normalization of dysregulated striatal DRD1 signalling in L-DOPA-treated rats.
    Azkona G; Sagarduy A; Aristieta A; Vazquez N; Zubillaga V; Ruíz-Ortega JA; Pérez-Navarro E; Ugedo L; Sánchez-Pernaute R
    Neuropharmacology; 2014 Apr; 79():726-37. PubMed ID: 24333147
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Motor response to a dopamine D3 receptor preferring agonist compared to apomorphine in levodopa-primed 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys.
    Blanchet PJ; Konitsiotis S; Chase TN
    J Pharmacol Exp Ther; 1997 Nov; 283(2):794-9. PubMed ID: 9353400
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low dose pramipexole is neuroprotective in the MPTP mouse model of Parkinson's disease, and downregulates the dopamine transporter via the D3 receptor.
    Joyce JN; Woolsey C; Ryoo H; Borwege S; Hagner D
    BMC Biol; 2004 Oct; 2():22. PubMed ID: 15473914
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of (-)-sesamin on motor and memory deficits in an MPTP-lesioned mouse model of Parkinson's disease treated with l-DOPA.
    Zhao TT; Shin KS; Kim KS; Park HJ; Kim HJ; Lee KE; Lee MK
    Neuroscience; 2016 Dec; 339():644-654. PubMed ID: 27789382
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pattern of levodopa-induced striatal changes is different in normal and MPTP-lesioned mice.
    Gross CE; Ravenscroft P; Dovero S; Jaber M; Bioulac B; Bezard E
    J Neurochem; 2003 Mar; 84(6):1246-55. PubMed ID: 12614325
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual motor response to l-dopa and nociceptin/orphanin FQ receptor antagonists in 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) treated mice: Paradoxical inhibition is relieved by D(2)/D(3) receptor blockade.
    Viaro R; Marti M; Morari M
    Exp Neurol; 2010 Jun; 223(2):473-84. PubMed ID: 20122926
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function.
    Bézard E; Ferry S; Mach U; Stark H; Leriche L; Boraud T; Gross C; Sokoloff P
    Nat Med; 2003 Jun; 9(6):762-7. PubMed ID: 12740572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of non-dopaminergic drug treatment on Levodopa induced dyskinesias in MPTP monkeys: common implication of striatal neuropeptides.
    Tamim MK; Samadi P; Morissette M; Grégoire L; Ouattara B; Lévesque D; Rouillard C; Di Paolo T
    Neuropharmacology; 2010 Jan; 58(1):286-96. PubMed ID: 19576910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of chronic levodopa treatment on pre- and postsynaptic markers of dopaminergic function in striatum of parkinsonian monkeys.
    Rioux L; Frohna PA; Joyce JN; Schneider JS
    Mov Disord; 1997 Mar; 12(2):148-58. PubMed ID: 9087972
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in glutamate receptors in dyskinetic parkinsonian monkeys after unilateral subthalamotomy.
    Jourdain VA; Morin N; Grégoire L; Morissette M; Di Paolo T
    J Neurosurg; 2015 Dec; 123(6):1383-93. PubMed ID: 25932606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early L-dopa, but not pramipexole, restores basal ganglia activity in partially 6-OHDA-lesioned rats.
    Marin C; Bonastre M; Mengod G; Cortés R; Giralt A; Obeso JA; Schapira AH
    Neurobiol Dis; 2014 Apr; 64():36-47. PubMed ID: 24370700
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MPEP, an mGlu5 receptor antagonist, reduces the development of L-DOPA-induced motor complications in de novo parkinsonian monkeys: biochemical correlates.
    Morin N; Grégoire L; Morissette M; Desrayaud S; Gomez-Mancilla B; Gasparini F; Di Paolo T
    Neuropharmacology; 2013 Mar; 66():355-64. PubMed ID: 22884464
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Brain 5-HT(2A) receptors in MPTP monkeys and levodopa-induced dyskinesias.
    Riahi G; Morissette M; Parent M; Di Paolo T
    Eur J Neurosci; 2011 May; 33(10):1823-31. PubMed ID: 21501255
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic treatment with MPEP, an mGlu5 receptor antagonist, normalizes basal ganglia glutamate neurotransmission in L-DOPA-treated parkinsonian monkeys.
    Morin N; Morissette M; Grégoire L; Gomez-Mancilla B; Gasparini F; Di Paolo T
    Neuropharmacology; 2013 Oct; 73():216-31. PubMed ID: 23756168
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.